Biomarkers in early cancer drug development: limited utility.
about
Micro-RNAs as potential new molecular biomarkers in oncology: have they reached relevance for the clinical imaging sciences?Pharmacokinetic/ pharmacodynamic-driven drug developmentAdvances in cancer therapeuticsProtein biomarker quantification by mass spectrometry.Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves' disease and orbitopathy.
P2860
Biomarkers in early cancer drug development: limited utility.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers in early cancer drug development: limited utility.
@en
Biomarkers in early cancer drug development: limited utility.
@nl
type
label
Biomarkers in early cancer drug development: limited utility.
@en
Biomarkers in early cancer drug development: limited utility.
@nl
prefLabel
Biomarkers in early cancer drug development: limited utility.
@en
Biomarkers in early cancer drug development: limited utility.
@nl
P2860
P356
P1476
Biomarkers in early cancer drug development: limited utility.
@en
P2093
M J Ratain
R H Glassman
P2860
P304
P356
10.1038/CLPT.2008.231
P407
P577
2009-02-01T00:00:00Z